Call us today: +1 (304) 470-2225
You can use WPML or Polylang and their language switchers in this area.

Renal Cancer–Competitive Landscape & Market Forecast

Renal Cancer Intelligence

Client Challenge

A mid-size Pharma wanted to evaluate the overall market size and potential of Renal cell carcinoma (RCC) by countries and therapies.


  • For evaluating the Market estimate, we used Hybrid Approach i.e., taking regard to both Patient-based and Sales based approaches. In view of the historical and current trends, we anticipate the market estimate for the next 10 years. 
  • We created the Market Forecast model considering factors such as epidemiology of the disease & its patient segmentations, unmet medical need, drug competitor factor, patient compliance, product price, marketed drugs- calibration based on actual sales and their impact in different geographies, emerging drugs and their impact, launch dates, market drivers and barriers, and other factors. 


  • Anticipated the total cases of Renal cell carcinoma during the forecast period for G7 (US, EU5, JP).
  • Evaluated and analyzed the emerging therapies, entering the market in the next 10 years.
  • Determined the competitive landscape of late-stage therapies entering the RCC market by the line of therapies. 
  • Quantified the market size of Renal cell carcinoma (RCC) by country and therapies.